 This virtual gathering of the global biotech industry provides access to partners via BIO One-on-One Partnering and educational resources. Capricor Therapeutics, Inc. CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment and prevention of diseases. Capricors lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. 